UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

Drug metabolism and disposition, 2018-07, Vol.46 (7), p.1001-1013

2018

Volltextzugriff (PDF)

Pharmacokinetic Properties of Mirabegron, a β3 -Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Clinical therapeutics, 2012-10, Vol.34 (10), p.2144-2160

2012

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0162322-e0162322

2023

Volltextzugriff (PDF)

Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects

Diabetes, obesity & metabolism, 2021-06, Vol.23 (6), p.1415-1419

2021

Volltextzugriff (PDF)

Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector

Diabetes, obesity & metabolism, 2022-08, Vol.24 (8), p.1643-1646

2022

Volltextzugriff (PDF)

Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects

Clinical pharmacokinetics, 2004, Vol.43 (7), p.479-486

2004

Volltextzugriff (PDF)

EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects

Clinical and translational science, 2023-02, Vol.16 (2), p.338-351

2023

Volltextzugriff (PDF)

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers

Journal of clinical pharmacology, 2000-12, Vol.40 (12), p.1312-1322

2000

Volltextzugriff (PDF)

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers

Clinical pharmacology: advances and applications, 2019-12, Vol.11, p.161-169

2019

Volltextzugriff (PDF)

EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects

Journal of hepatology, 2022-07, Vol.77, p.S716-S717

2022

Volltextzugriff (PDF)

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants

Antimicrobial agents and chemotherapy, 2024-05

2024

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants

Antimicrobial agents and chemotherapy, 2024-05, Vol.68 (5), p.e0145523

2024

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects

Clinical pharmacology and therapeutics, 1996-08, Vol.60 (2), p.124-137

1996

Volltextzugriff (PDF)

Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers

Journal of clinical pharmacology, 1999-07, Vol.39 (7), p.703-714

1999

Volltextzugriff (PDF)

Hypertensive crisis-induced electrocardiographic changes: a case series

Journal of medical case reports, 2009-08, Vol.3 (1), p.7283-7283

2009

Volltextzugriff (PDF)

Metabolism and Disposition of Siponimod, a Novel Selective S1P 1 /S1P 5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

Drug metabolism and disposition, 2018-07, Vol.46 (7), p.1001-1013

2018

Volltextzugriff (PDF)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of 14C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder

International journal of clinical pharmacology and therapeutics, 2012-11, Vol.50 (11), p.838

2012

Volltextzugriff (PDF)

Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans

Xenobiotica, 2013-06, Vol.43 (6), p.534-547

2013

Volltextzugriff (PDF)

Pharmacokinetic Characterization of the Novel Pulmonary Delivery Excipient Fumaryl Diketopiperazine

Journal of diabetes science and technology, 2010-09, Vol.4 (5), p.1164-1173

2010

Volltextzugriff (PDF)

Sugammadex is cleared rapidly and primarily unchanged via renal excretion

Biopharmaceutics & drug disposition, 2011-04, Vol.32 (3), p.159-167

2011

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

BMC pharmacology & toxicology, 2013-02, Vol.14 (1), p.14-14, Article 14

2013

Volltextzugriff (PDF)

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S526-S526

2017

Volltextzugriff (PDF)

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S534-S534

2017

Volltextzugriff (PDF)

Pharmacokinetic Properties of Mirabegron, a [beta]3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Clinical therapeutics, 2012-10, Vol.34 (10), p.2144

2012

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(31)
Berichte
(1)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

Pharmacokinetic Properties of Mirabegron, a β3 -Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects

Comparison of the injection‐site experience of semaglutide in a single‐dose and a multidose pen‐injector

Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects

EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers

EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants

Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects

Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers

Hypertensive crisis-induced electrocardiographic changes: a case series

Metabolism and Disposition of Siponimod, a Novel Selective S1P 1 /S1P 5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of 14C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder

Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans

Pharmacokinetic Characterization of the Novel Pulmonary Delivery Excipient Fumaryl Diketopiperazine

Sugammadex is cleared rapidly and primarily unchanged via renal excretion

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

Pharmacokinetic Properties of Mirabegron, a [beta]3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women

Suchergebnisse filtern